Threshold Pharmaceuticals (THLD) Shares are Up 49.67%

Threshold Pharmaceuticals (THLD) : Traders are bullish on Threshold Pharmaceuticals (THLD) as it has outperformed the S&P 500 by a wide margin of 81.2% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 49.72%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 49.67% in the last 1 week, and is up 81.9% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Threshold Pharmaceuticals Inc. is up 123.13% in the last 3-month period. Year-to-Date the stock performance stands at 81.29%. The stock has recorded a 20-day Moving Average of 47.62% and the 50-Day Moving Average is 59.96%.


Threshold Pharmaceuticals (NASDAQ:THLD): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $0.78 and $0.78 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $0.98. The buying momentum continued till the end and the stock did not give up its gains. It closed at $0.87, notching a gain of 11.71% for the day. The total traded volume was 5,653,514 . The stock had closed at $0.78 on the previous day.

Threshold Pharmaceuticals, Inc. (Threshold) is a biotechnology company engaged in the discovery and development of therapeutic agents that selectively target tumor cells for the treatment of patients living with cancer. Thresholds investigational small molecule, evofosfamide, is being evaluated in two Phase III clinical trials, one registrational Phase II clinical trial and various earlier-stage clinical trials for the treatment of various diseases, such as soft tissue sarcoma, pancreatic cancer, non-squamous non-small cell lung cancer (n-s NSCLC), advanced melanoma, multiple myeloma and advanced solid tumors. Threshold has also licensed rights to a development program based on the clinical-stage oncology compound TH-4000, a hypoxia-targeted epidermal growth factor receptor (EGFR), tyrosine kinase inhibitor. Thresholds [18F]-HX4 is an investigational Positron Emission Tomography (PET) imaging agent for hypoxia to identify and quantify the degree of hypoxia in tumors in vivo.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *